Cervical cancer is currently the fourth leading cause of cancer death among women worldwide, with most cases occurring in low-and middle-income countries. Safe, highly effective vaccines against HPV have been on the market since 2006, yet only 6% of girls worldwide have received this life-saving cancer prevention intervention.
| INTRODUCTION
Cervical cancer, almost entirely attributable to HPV, is the fourth leading cause of cancer in women worldwide. 1 The vast majority of the 528 000 new cases and 266 000 cervical cancer deaths reported each year occur in low-and middle-income countries (LMICs) among women whose access to cervical cancer screening, treatment, and palliative care is either limited or nonexistent. 1 To date, the benefits of primary prevention-vaccination against HPV-are also largely unrecognized in LMICs. are covered by all three vaccines, whereas types 31, 33, 45, 52, and 58, found in 9vHPV, account for an additional 19% of all cervical cancers ( Fig. 1) . 2 Prophylactic vaccines have been evaluated in more than 75 000 women and men in clinical trials conducted globally with up to 10 years of follow-up. All three are highly immunogenic, efficacious, and safe (Table 1) . [3] [4] [5] Importantly, their immunogenicity and safety have also been demonstrated in HIV-infected individuals, who are at two-to five-fold increased risk of HPV-associated anogenital cancers. 6 In a combined analysis of four randomized controlled trials of 4vHPV enrolling more than 20 000 women, vaccination reduced the risk of HPV-16/18-related cervical intraepithelial neoplasia (CIN) 2/3+ (defined as CIN2/3, adenocarcinoma in-situ, or invasive cervical cancer) by 99% among HPV-naïve women. 7 Similarly, in the PApilloma TRIal against Cancer In young Adults (PATRICIA) of 2vHPV, HPV-16/18-related CIN3+ was reduced by 93% in an HPV-naïve population. 8 In a phase 3 trial of 9vHPV, this vaccine led to a 97% reduction in the combined incidence of HPV- with nearly 100 000 patient-years of follow-up, no cases of cervical cancer were reported in the vaccinated group. 13 Current WHO recommendations endorse nationwide HPV vaccination programs targeting girls aged 9-14 years. 12 The rationale for focusing on preadolescent and adolescent girls is that vaccine efficacy declines considerably among women previously exposed to HPV.
Although per-protocol analyses from, for example, the FUTURE II (4vHPV) and PATRICA (2vHPV) trials demonstrate a strong protective effect of vaccination (93%-99%), the efficacy was substantially lower (44%-46%) in the intention-to-treat analyses, which included girls with prior HPV infection. 
| PROJECTED IMPACT OF HPV VACCINATION
If implemented at scale, HPV vaccination will likely prevent millions of deaths from cervical cancer, particularly in LMICs. The primary evidence for reductions in cancer incidence and mortality attributable to HPV vaccination is derived from epidemiologic models; we highlight five such models here, focusing on cervical cancer outcomes ( 20 provides useful insight by estimating the reductions in the cervical cancer incidence following 2v-, 4v-, or 9vHPV vaccination. In this model, 2vHPV is associated with greater reductions in the cervical cancer incidence than is 4vHPV (62% versus 59%) because of the higher cross-protective efficacy of 2vHPV. However, switching from 4vHPV to 2vHPV would only prevent an additional 3% of CIN2/3
cases over a 70-year period and would result in a 63% increase in anogenital warts. By contrast, switching from 2v-or 4vHPV to 9vHPV is estimated to reduce the incidence of CIN2/3 by 9%-13% over the long term because of the coverage of additional high-risk HPV types. 20 Although epidemiologic models are helpful in framing programmatic and policy discussions, it is important to note that such models are limited by the quality of the data available for the parameter estimates and by their underlying assumptions. The data available on HPV vaccination, especially as they relate to LMICs, are of relatively poor quality.
Additionally, all five models assume that vaccination confers lifelong protection against HPV infection, despite the fact that only 10 years of follow-up data are available from clinical trials. 6, 11 With the exception of Van de Velde et al., 20 all authors assume 100% efficacy, whereas efficacy rates around 95% are likely more realistic. 
| HPV VACCINE IMPLEMENTATION AND COVERAGE IN LMICS
To better illustrate worldwide HPV vaccine implementation and coverage, we have created an online data visualization tool using Tableau 
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Oberlin eT Al. To achieve maximal benefit, HPV vaccination programs must ensure high coverage levels in the target population. In LMICs, this is typically preadolescent girls aged 9 years and older. 21 Figure 4A ,B illustrate major public health failures to achieve adequate vaccine coverage in both rich and poor countries. Although data are sparse and may also be of poor quality, we note wide variation in full-course vaccine coverage, defined as the proportion of girls in the target population receiving two or three doses of vaccine. Among 50 countries with publicly available coverage data from national HPV vaccination programs, the median full-dose coverage was 68% (interquartile range, 46%-84%); the results ranged from 8% in Ecuador to 97% in Botswana and Rwanda. [31] [32] [33] [34] [35] Acceptability of the HPV vaccine is also an important factor in achieving high vaccine coverage and should be addressed contemporaneously with structural barriers to vaccine access. per dose is well below the market price, the true manufacturing costs are estimated at US$2.07-3.05 per dose for the first set manufactured in a given year, because of high fixed costs, but are at only US$0.48-0.59 per dose for a second set. 38 Therefore, as programs mature, the additional cost per dose is anticipated to fall. 40 
| NATIONAL HPV VACCINATION PROGRAMS

| Single-dose HPV vaccination
All available HPV vaccines are currently approved as a two-dose series in girls younger than 15 years of age and a three-dose series in girls 15 years or older, with the doses given over a period of at least 6 months. 12 If proven effective, single-dose HPV vaccination (without the need for a booster dose) would be simpler and more affordable than current dosing schedules, decreasing the burden on public health systems in LMICs. 41 Switching to a single-dose schedule is also anticipated to increase vaccination coverage levels (Fig. S3 ). Current estimates from national programs indicate that the median coverage drops from 85% (interquartile range 46%-84%) for single-dose vaccination to 68% (interquartile range 61%-89%) for two-or threedose vaccination. 31 Emerging evidence to support this approach includes an observational cohort study conducted in India, 42 in which the immunogenicity (measured by geometric mean avidity) for one dose of 4vHPV was noninferior to that for three doses. After nearly 5 years of follow-up, the risk of HPV-16/18 infection reported among girls in the one-dose vaccine group compared with those in the threedose group was similar (1.1% versus 0.4%). Additionally, a post-hoc analysis of two 2vHPV trials found that 4 years after vaccination, the efficacy against HPV-16/18 was 77% for three doses and 86%
for one dose of the vaccine (P=0.36). 43 The Costa Rica Vaccine Trial
Group has demonstrated no significant differences in cumulative HPV infections between one, two, and three doses of the 2vHPV vaccine. 44 The group is currently conducting a randomized trial to determine the efficacy of one-and two-dose schedules of the 2vHPV and 9vHPV vaccines in girls and women aged 12-20 years (ClinicalTrials.gov: NCT03180034).
As evidence and enthusiasm for single-dose HPV vaccination evolves, special consideration will be required for HIV-infected individuals, for whom only the three-dose HPV vaccine schedule is currently recommended. 12 This is of great significance to policymakers in Sub-Saharan Africa, where many countries are experiencing generalized HIV epidemics with large numbers of HIV-infected young women, whose lifetime risk of cervical cancer is substantial.
| Co-administration of the HPV vaccine
Co-administration of the HPV vaccine with other routine adolescent vaccines (Fig. 6) Coverage is defined as the proportion of the targeted population receiving a one-dose vaccine.
